Cargando…

Fondaparinux: A cornerstone drug in acute coronary syndromes

In acute coronary syndrome (ACS), the use of anticoagulants in conjunction with antiplatelet agents in the acute phase has resulted in reduced ischemic events and is more effective than either class of drug used alone. Though parenteral anticoagulation is essential at the time of diagnosis, a balanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Mohammed Yunus, Ponde, Chandrashekhar K, Kumar, Viveka, Gaurav, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788176/
https://www.ncbi.nlm.nih.gov/pubmed/35126871
http://dx.doi.org/10.4330/wjc.v14.i1.40
_version_ 1784639502776532992
author Khan, Mohammed Yunus
Ponde, Chandrashekhar K
Kumar, Viveka
Gaurav, Kumar
author_facet Khan, Mohammed Yunus
Ponde, Chandrashekhar K
Kumar, Viveka
Gaurav, Kumar
author_sort Khan, Mohammed Yunus
collection PubMed
description In acute coronary syndrome (ACS), the use of anticoagulants in conjunction with antiplatelet agents in the acute phase has resulted in reduced ischemic events and is more effective than either class of drug used alone. Though parenteral anticoagulation is essential at the time of diagnosis, a balance must be made between ischemic benefit and the increased risk of bleeding when prescribing anticoagulants. Adverse events associated with anticoagulants, such as heparin-induced thrombocytopenia, bleeding problems, and the need for close monitoring of anticoagulant activity, have contributed to finding agents that reduce these limitations. Studies like the Organization to Assess Strategies in Ischemic Syndromes 5 and 6 and their meta-analysis have proven the efficacy of Fondaparinux over the entire ACS spectrum. The convenience of administration (once daily), lack of monitoring, reduction in mortality, and better safety profile make Fondaparinux a simple and effective anti-coagulant for the management of ACS.
format Online
Article
Text
id pubmed-8788176
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-87881762022-02-03 Fondaparinux: A cornerstone drug in acute coronary syndromes Khan, Mohammed Yunus Ponde, Chandrashekhar K Kumar, Viveka Gaurav, Kumar World J Cardiol Minireviews In acute coronary syndrome (ACS), the use of anticoagulants in conjunction with antiplatelet agents in the acute phase has resulted in reduced ischemic events and is more effective than either class of drug used alone. Though parenteral anticoagulation is essential at the time of diagnosis, a balance must be made between ischemic benefit and the increased risk of bleeding when prescribing anticoagulants. Adverse events associated with anticoagulants, such as heparin-induced thrombocytopenia, bleeding problems, and the need for close monitoring of anticoagulant activity, have contributed to finding agents that reduce these limitations. Studies like the Organization to Assess Strategies in Ischemic Syndromes 5 and 6 and their meta-analysis have proven the efficacy of Fondaparinux over the entire ACS spectrum. The convenience of administration (once daily), lack of monitoring, reduction in mortality, and better safety profile make Fondaparinux a simple and effective anti-coagulant for the management of ACS. Baishideng Publishing Group Inc 2022-01-26 2022-01-26 /pmc/articles/PMC8788176/ /pubmed/35126871 http://dx.doi.org/10.4330/wjc.v14.i1.40 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Minireviews
Khan, Mohammed Yunus
Ponde, Chandrashekhar K
Kumar, Viveka
Gaurav, Kumar
Fondaparinux: A cornerstone drug in acute coronary syndromes
title Fondaparinux: A cornerstone drug in acute coronary syndromes
title_full Fondaparinux: A cornerstone drug in acute coronary syndromes
title_fullStr Fondaparinux: A cornerstone drug in acute coronary syndromes
title_full_unstemmed Fondaparinux: A cornerstone drug in acute coronary syndromes
title_short Fondaparinux: A cornerstone drug in acute coronary syndromes
title_sort fondaparinux: a cornerstone drug in acute coronary syndromes
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788176/
https://www.ncbi.nlm.nih.gov/pubmed/35126871
http://dx.doi.org/10.4330/wjc.v14.i1.40
work_keys_str_mv AT khanmohammedyunus fondaparinuxacornerstonedruginacutecoronarysyndromes
AT pondechandrashekhark fondaparinuxacornerstonedruginacutecoronarysyndromes
AT kumarviveka fondaparinuxacornerstonedruginacutecoronarysyndromes
AT gauravkumar fondaparinuxacornerstonedruginacutecoronarysyndromes